Phase I Study of Lonsurf in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Ductal Adenocarcinoma (PDAC)

Study Overview

The purpose of this study is to see whether a chemotherapy drug called Lonsurf (TAS-102) could be given safely with other chemotherapy agents (gemcitabine and nab-paclitaxel), and to assess the good and bad effects this treatment might have. Gemcitabine and nab-paclitaxel are approved by the Food and Drug Administration (FDA) for the treatment of pancreatic cancer.

  • IRB Number: 1811447298 (IUSCC-0664)
  • Research Study Identifier: TX10501
  • Principal Investigator: Patrick Loehrer, MD

Recruitment Status


Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Volunteer Sign up

Volunteer Registry

Create your profile and be matched to research opportunities

Register Now!

Contact Us

If you need help finding a study or have any questions, please contact us at or by phone at (888) 264-0005.